Biosearch Life applies for a new patent for the treatment of female infertility
Studies have shown that the CECT5713 strain of Lactobacillus Salivarius allowed pregnancies to be 66% effective in women with infertility of unknown cause
Biosearch Life, a biotechnology company focused on providing innovative solutions worldwide with over 20 years of experience in the research, development, manufacture and marketing of natural ingredients, has applied for a new patent for a probiotic strain for infertility problems in women. It would become the first probiotic-based product for this treatment.
Currently, 15% of couples are estimated to have fertility problems. The cause of the problem is attributed in 30% of cases to women, 30% in men and in 25% of cases to both, but the cause is unknown in the remaining 15% of cases.
According to recent studies, there is increasing evidence showing the relevance of the microbiota from the female reproductive tract in human reproduction. Under physiological conditions and in contrast to the intestinal microbiota, the human vaginal microbiota is generally distinguished by low bacterial diversity and the abundance and predominance of bacteria of the Lactobacillus genus.
Research carried out by the Complutense University of Madrid in collaboration with Biosearch Life shows how the oral administration of the Lactobacillus Salivarius CECT5713 strain to women with infertility or with recurrent and unexplained pregnancy loss, allowed pregnancies to be achieved with 66% effectiveness, and with a reproductive success of 56%. These results represent an important milestone in the treatment of infertility of unknown causes, which could be associated with imbalances in the microbiota of the female reproductive tract.
With this new patent, the third that the company has applied for so far this year, Biosearch Life continues its trajectory in the search for solutions to fertility problems in women through natural solutions. This R&D line began in 2017 with a patent on the use of a specific combination of myo-inositol and D-chiro-inositol for infertility treatment in women with Polycystic Ovary Syndrome. The new product will be launched globally and on the pharmaceutical market.
The global fertility supplement market was valued at 1.470 million dollars in 2019. Between 2019 and 2029 this market is expected to increase at a compound annual rate of 7.8%. At regional level, North America is currently the market leader. However, over the next few years, Asia Pacific is likely to experience a higher growth rate. The trend in demand in this market leans towards products that include natural ingredients, therefore it is of great interest to Biosearch Life.
In the words of Jose María Roset, Biosearch Life CEO: “At Biosearch Life, research and development is part of our DNA and is a fundamental factor in our business strategy. Products that we will develop through patents such as the one we have just applied for, also have a direct impact on the lives of many couples who are currently experiencing difficulties in having a family. It is therefore twice as satisfying to see the result of years of research and effort in a real product, which will also provide solutions in such a sensitive area for so many families as conception, and very important for the future of our society".